GSK plc (LON:GSK) Stock Has Consensus Price Target of GBX 2,064.38 According to Analysts

Shares of GSK plc (LON:GSK) have received an average recommendation of “Hold” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is GBX 2,064.38.

Several research firms have recently issued reports on GSK. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a research report on Tuesday, October 20th. Berenberg Bank raised their target price on shares of GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a research note on Tuesday, September 15th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a report on Thursday. Finally, Royal Bank Of Canada began coverage on shares of GSK in a research note on Tuesday, September 8th. They issued a “sector perform” rating and a GBX 1,975 price target on the stock.

GSK Trading Up 2.0%

Shares of GSK stock opened at GBX 1,850 on Friday. The company has a market capitalization of £74.13 billion, a P/E ratio of 15.70, a P/E/G ratio of 1.24 and a beta of 0.28. The company has a debt-to-equity ratio of 126.38, a quick ratio of 0.73 and a current ratio of 0.86. The company has a fifty day moving average of GBX 1,845.48 and a 200 day moving average of GBX 1,948.89. GSK has a fifty-two week low of GBX 1,690 and a fifty-two week high of GBX 2,282.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, October 28th. The company reported GBX 54.60 earnings per share (EPS) for the quarter. The business had revenue of GBX 888.70 billion during the quarter. GSK had a return on equity of 24.64% and a net margin of 12.97%. On average, sell-side analysts anticipate that GSK will post 175.98 earnings per share for the current fiscal year.

Insider Activity at GSK

In related news, insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction dated Friday, September 18th. The stock was acquired at an average cost of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal bought 637 shares of the stock in a transaction dated Friday, September 18th. The stock was purchased at an average price of GBX 4,985 per share, with a total value of £31,754.45. Insiders have acquired a total of 2,151 shares of company stock valued at $6,021,921 in the last 90 days. 0.20% of the stock is currently owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.